6-氯-8-乙基-9H-嘌呤 | 92001-53-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 6-氯-8-乙基-9H-嘌呤
• 英文名称: 6-chloro-8-ethyl-9H-purine
• 英文别名: 6-chloro-8-ethyl-7(9)H-purine；6-Chlor-8-ethyl-purin；6-chloro-8-ethyl-7H-purine
• CAS: 92001-53-1
• 化学式: C₇H₇ClN₄
• mdl: MFCD09863912
• 分子量: 182.612
• InChiKey: PNSVJHYYAASBNE-UHFFFAOYSA-N

物化性质

• 熔点：
  170-172 °C (decomp)
• 沸点：
  250.1±50.0 °C(Predicted)
• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-氯-8-乙基-9H-嘌呤 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(9-([1,1'-biphenyl]-4-ylmethyl)-8-ethyl-9H-purin-6-yl)morpholine
  参考文献：
  名称：

  Design and optimization of purine derivatives as in vivo active PDE10A inhibitors

  摘要：

  Phosphodiesterases are important enzymes regulating signal transduction mediated by second messenger molecules cAMP or cGMP. PDE10A is a unique member in the PDE family because of its selective expression in medium spiny neurons. It is recognized as anti-psychotic drug target. Based on the structural similarity between our previous chemistry work on 8-aminoimidazo[1,2-alpyrazines and the PDE10A inhibitors reported by Bartolome-Nebreda et al., we initialized a project for developing PDE10A inhibitors. After several rounds of optimization, we were able to obtain a few compounds with good PDE10A enzymatic activity. And after further PDE enzymatic selectivity study, metabolic stability assay and in vivo pharmacological tests we identified two inhibitors as interesting lead compounds with the potential for further PDE10A lead optimizatioin. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.04.019
• 作为产物：
  描述：

  N-(6-氨基-4-氧代-1H-嘧啶-5-基)丙酰胺 在 N,N-二乙基苯胺 、 三氯氧磷 作用下， 反应 6.0h， 以52%的产率得到6-氯-8-乙基-9H-嘌呤
  参考文献：
  名称：

  Mornet, Rene; Leonard, Nelson J.; Theiler, Jane B., Journal of the Chemical Society. Perkin transactions I, 1984, # 5, p. 879 - 885

  摘要：

  DOI：

文献信息

• Piperazine and homopiperazine compounds
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20030153556A1

  公开（公告）日：2003-08-14

  Compounds are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis.

  提供了具有哌嗪或同源哌嗪环的化合物，这些化合物在治疗血栓症方面很有用。
• Structure-based design, synthesis, and antimicrobial activity of purine derived SAH/MTA nucleosidase inhibitors
  作者：Martina E. Tedder、Zhe Nie、Stephen Margosiak、Shaosong Chu、Victoria A. Feher、Robert Almassy、Krzysztof Appelt、Kraig M. Yager

  DOI：10.1016/j.bmcl.2004.04.006

  日期：2004.6

  The structure-based design, synthesis, and biological activity of novel inhibitors of S-adenosyl homocysteine/methylthioadenosine (SAH/MTA) nucleosidase are described. Using 6-substituted purine and deaza purines as the core scaffolds, a systematic and structure guided series of modifications provided low nM inhibitors with broad-spectrum antimicrobial activity. (C) 2004 Elsevier Ltd. All rights reserved.
• MORNET, R.;LEONARD, N. J.;THEILER, J. B.;DOREE, M., J. CHEM. SOC. PERKIN TRANS., 1984, N 5, 879-885
  作者：MORNET, R.、LEONARD, N. J.、THEILER, J. B.、DOREE, M.

  DOI：——

  日期：——
• US7115741B2
  申请人：——

  公开号：US7115741B2

  公开（公告）日：2006-10-03
• [EN] PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS<br/>[FR] COMPOSES A BASE DE PIPERAZINE ET D'HOMOPIPERAZINE
  申请人：MILLENNIUM PHARM INC

  公开号：WO2003022214A2

  公开（公告）日：2003-03-20

  Compounds are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis.